Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 12 points (-0.1%) at 16,797 as of Wednesday, June 18, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,344 issues advancing vs. 1,611 declining with 185 unchanged. The Drugs industry currently sits up 0.1% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Gilead ( GILD), down 1.0%, and Novo Nordisk A/S ( NVO), down 0.6%. Top gainers within the industry include Shire ( SHPG), up 2.5%, Teva Pharmaceutical Industries ( TEVA), up 1.2%, Biogen Idec ( BIIB), up 1.2%, Allergan ( AGN), up 1.1% and Actavis ( ACT), up 0.9%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Sanofi ( SNY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sanofi is down $0.35 (-0.7%) to $53.66 on light volume. Thus far, 304,723 shares of Sanofi exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $53.63-$54.04 after having opened the day at $54.02 as compared to the previous trading day's close of $54.01. Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Sanofi has a market cap of $142.6 billion and is part of the health care sector. Shares are up 0.7% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, growth in earnings per share, increase in net income and increase in stock price during the past year. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Sanofi Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.